{"title":"The VExUS score and mortality in patients with Acute Kidney Injury: findings from a multidisciplinary prospective study.","authors":"Mehmet Ali Aslaner, Özant Helvacı, Korbin Haycock","doi":"10.11152/mu-4418","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The utility of the venous excess ultrasound (VExUS) score in predicting mortality remains uncertain in acute kidney injury (AKI) patients.</p><p><strong>Material and methods: </strong>This was a post-hoc study involving 246 AKI patients presenting to a tertiary care emergency department. Venous ultrasound assessments were conducted to determine the VExUS score. Cox regressionanalysis was used to identify predictors of 6-month mortality.</p><p><strong>Results: </strong>The study found no significant association between the VExUS score and 6-month mortality in AKI patients in the regression analyses. However, in the subgroup analyses, VExUS grades 2-3 were associated with lower survival rates in the cardiorenal subgroup (HR: 3.98 [95% CI: 1.33-11.93]), and in AKI grade 1 (HR: 4.07 [95% CI: 1.74-9.49]). This association was not present in other AKI subgroups. The predictors of mortality included higher age (OR: 1.024; 95% CI 1.005-1.043), malignancy (OR: 2.186; 95% CI 1.408-3.392), lower systolic blood pressure (OR: 0.990; 95% CI 0.982-0.998), elevated pulse (OR: 1.013; 95% CI 1.005-1.022), and higher lactate levels (OR: 1.210; 95% CI 1.097-1.334).</p><p><strong>Conclusion: </strong>The VExUS score did not predict 6-month mortality in the general cohort of AKI patients in the emergency department. However, VExUS grades 2-3 were associated with lower survival rates in the cardiorenal subgroup and patients with AKI grade 1.</p>","PeriodicalId":94138,"journal":{"name":"Medical ultrasonography","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical ultrasonography","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11152/mu-4418","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: The utility of the venous excess ultrasound (VExUS) score in predicting mortality remains uncertain in acute kidney injury (AKI) patients.
Material and methods: This was a post-hoc study involving 246 AKI patients presenting to a tertiary care emergency department. Venous ultrasound assessments were conducted to determine the VExUS score. Cox regressionanalysis was used to identify predictors of 6-month mortality.
Results: The study found no significant association between the VExUS score and 6-month mortality in AKI patients in the regression analyses. However, in the subgroup analyses, VExUS grades 2-3 were associated with lower survival rates in the cardiorenal subgroup (HR: 3.98 [95% CI: 1.33-11.93]), and in AKI grade 1 (HR: 4.07 [95% CI: 1.74-9.49]). This association was not present in other AKI subgroups. The predictors of mortality included higher age (OR: 1.024; 95% CI 1.005-1.043), malignancy (OR: 2.186; 95% CI 1.408-3.392), lower systolic blood pressure (OR: 0.990; 95% CI 0.982-0.998), elevated pulse (OR: 1.013; 95% CI 1.005-1.022), and higher lactate levels (OR: 1.210; 95% CI 1.097-1.334).
Conclusion: The VExUS score did not predict 6-month mortality in the general cohort of AKI patients in the emergency department. However, VExUS grades 2-3 were associated with lower survival rates in the cardiorenal subgroup and patients with AKI grade 1.
目的:静脉超量超声(VExUS)评分在预测急性肾损伤(AKI)患者死亡率方面的效用仍不确定:这是一项事后研究,涉及 246 名到三级医院急诊科就诊的 AKI 患者。进行静脉超声评估以确定 VExUS 评分。采用 Cox 回归分析确定 6 个月死亡率的预测因素:结果:研究发现,在回归分析中,VExUS评分与AKI患者6个月死亡率无明显关联。然而,在亚组分析中,VExUS 2-3 级与心肾(HR:3.98 [95% CI:1.33-11.93])亚组和 AKI 1 级(HR:4.07 [95% CI:1.74-9.49])亚组较低的存活率相关。这种关联在其他 AKI 亚组中并不存在。预测死亡率的因素包括年龄较大(OR:1.024;95% CI 1.005-1.043)、恶性肿瘤(OR:2.186;95% CI 1.408-3.392)、收缩压较低(OR:0.990;95% CI 0.982-0.998)、脉搏升高(OR:1.013;95% CI 1.005-1.022)和乳酸水平较高(OR:1.210;95% CI 1.097-1.334):结论:VExUS评分不能预测急诊科AKI患者的6个月死亡率。结论:VExUS评分并不能预测急诊科AKI患者的6个月死亡率,但VExUS 2-3级与心肾功能亚组和AKI 1级患者较低的存活率有关。